Does the media favor IBRX or NRIX?

In the previous week, Nurix Therapeutics had 12 more articles in the media than ImmunityBio. MarketBeat recorded 22 mentions for Nurix Therapeutics and 10 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.32 beat Nurix Therapeutics' score of 0.30 indicating that ImmunityBio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ImmunityBio 2 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nurix Therapeutics 3 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer NUVL or NRIX?

In the previous week, Nurix Therapeutics had 12 more articles in the media than Nuvalent. MarketBeat recorded 22 mentions for Nurix Therapeutics and 10 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.52 beat Nurix Therapeutics' score of 0.30 indicating that Nuvalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 3 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to KYMR or NRIX?

In the previous week, Nurix Therapeutics had 12 more articles in the media than Kymera Therapeutics. MarketBeat recorded 22 mentions for Nurix Therapeutics and 10 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.50 beat Nurix Therapeutics' score of 0.30 indicating that Kymera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 3 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media favor NRIX or PRAX?

In the previous week, Nurix Therapeutics had 16 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 22 mentions for Nurix Therapeutics and 6 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.75 beat Nurix Therapeutics' score of 0.30 indicating that Praxis Precision Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nurix Therapeutics 3 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Praxis Precision Medicines 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PTGX or NRIX?

In the previous week, Nurix Therapeutics had 12 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 22 mentions for Nurix Therapeutics and 10 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.67 beat Nurix Therapeutics' score of 0.30 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 3 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Nurix Therapeutics (NRIX) Competitors

$22.71 -0.35 (-1.52%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$22.63 -0.08 (-0.35%)

As of 07/13/2026 07:46 PM Eastern

Compare

NRIX vs. IBRX, NUVL, KYMR, PRAX, and PTGX

Should you buy Nurix Therapeutics stock or one of its competitors? MarketBeat compares Nurix Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nurix Therapeutics include ImmunityBio (IBRX), Nuvalent (NUVL), Kymera Therapeutics (KYMR), Praxis Precision Medicines (PRAX), and Protagonist Therapeutics (PTGX). These companies are all part of the "pharmaceutical products" industry.

How does Nurix Therapeutics compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Nurix Therapeutics (NASDAQ:NRIX) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

Nurix Therapeutics has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ImmunityBio	$113.29M	72.02	-$351.40M	-$0.85	N/A
Nurix Therapeutics	$83.98M	28.06	-$264.46M	-$3.45	N/A

ImmunityBio presently has a consensus price target of $14.20, suggesting a potential upside of 82.28%. Nurix Therapeutics has a consensus price target of $34.08, suggesting a potential upside of 50.05%. Given ImmunityBio's higher possible upside, analysts clearly believe ImmunityBio is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

ImmunityBio has a net margin of -606.15% compared to Nurix Therapeutics' net margin of -928.44%. ImmunityBio's return on equity of 0.00% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ImmunityBio	-606.15%	N/A	-59.53%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

In the previous week, Nurix Therapeutics had 12 more articles in the media than ImmunityBio. MarketBeat recorded 22 mentions for Nurix Therapeutics and 10 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 0.32 beat Nurix Therapeutics' score of 0.30 indicating that ImmunityBio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ImmunityBio	2 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nurix Therapeutics	3 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

ImmunityBio has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

8.6% of ImmunityBio shares are held by institutional investors. 66.1% of ImmunityBio shares are held by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

ImmunityBio beats Nurix Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Nurix Therapeutics compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Nurix Therapeutics (NASDAQ:NRIX) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

97.3% of Nuvalent shares are held by institutional investors. 5.0% of Nuvalent shares are held by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nuvalent presently has a consensus price target of $127.73, indicating a potential upside of 3.06%. Nurix Therapeutics has a consensus price target of $34.08, indicating a potential upside of 50.05%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Nurix Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Nuvalent has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

Nurix Therapeutics has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Nurix Therapeutics	$83.98M	28.06	-$264.46M	-$3.45	N/A

In the previous week, Nurix Therapeutics had 12 more articles in the media than Nuvalent. MarketBeat recorded 22 mentions for Nurix Therapeutics and 10 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.52 beat Nurix Therapeutics' score of 0.30 indicating that Nuvalent is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nurix Therapeutics	3 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Nuvalent has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Nuvalent's return on equity of -40.11% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

Summary

Nurix Therapeutics beats Nuvalent on 10 of the 15 factors compared between the two stocks.

How does Nurix Therapeutics compare to Kymera Therapeutics?

Kymera Therapeutics (NASDAQ:KYMR) and Nurix Therapeutics (NASDAQ:NRIX) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Kymera Therapeutics has a net margin of -611.94% compared to Nurix Therapeutics' net margin of -928.44%. Kymera Therapeutics' return on equity of -24.71% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-611.94%	-24.71%	-22.05%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

Kymera Therapeutics has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

Kymera Therapeutics presently has a consensus target price of $121.73, indicating a potential upside of 10.26%. Nurix Therapeutics has a consensus target price of $34.08, indicating a potential upside of 50.05%. Given Nurix Therapeutics' higher probable upside, analysts plainly believe Nurix Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.91
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Nurix Therapeutics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kymera Therapeutics	$39.21M	231.61	-$311.35M	-$3.57	N/A
Nurix Therapeutics	$83.98M	28.06	-$264.46M	-$3.45	N/A

In the previous week, Nurix Therapeutics had 12 more articles in the media than Kymera Therapeutics. MarketBeat recorded 22 mentions for Nurix Therapeutics and 10 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.50 beat Nurix Therapeutics' score of 0.30 indicating that Kymera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kymera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Nurix Therapeutics	3 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Kymera Therapeutics beats Nurix Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Nurix Therapeutics compare to Praxis Precision Medicines?

Nurix Therapeutics (NASDAQ:NRIX) and Praxis Precision Medicines (NASDAQ:PRAX) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Nurix Therapeutics presently has a consensus target price of $34.08, indicating a potential upside of 50.05%. Praxis Precision Medicines has a consensus target price of $563.50, indicating a potential upside of 79.14%. Given Praxis Precision Medicines' stronger consensus rating and higher probable upside, analysts plainly believe Praxis Precision Medicines is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Praxis Precision Medicines	2 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	4 Strong Buy rating(s)	2.95

In the previous week, Nurix Therapeutics had 16 more articles in the media than Praxis Precision Medicines. MarketBeat recorded 22 mentions for Nurix Therapeutics and 6 mentions for Praxis Precision Medicines. Praxis Precision Medicines' average media sentiment score of 0.75 beat Nurix Therapeutics' score of 0.30 indicating that Praxis Precision Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nurix Therapeutics	3 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Praxis Precision Medicines	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

67.8% of Praxis Precision Medicines shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by insiders. Comparatively, 3.0% of Praxis Precision Medicines shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Nurix Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, Praxis Precision Medicines has a beta of 2.74, indicating that its share price is 174% more volatile than the broader market.

Praxis Precision Medicines has a net margin of 0.00% compared to Nurix Therapeutics' net margin of -928.44%. Praxis Precision Medicines' return on equity of -43.02% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nurix Therapeutics	-928.44%	-76.09%	-57.31%
Praxis Precision Medicines	N/A	-43.02%	-40.22%

Nurix Therapeutics has higher revenue and earnings than Praxis Precision Medicines. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nurix Therapeutics	$83.98M	28.06	-$264.46M	-$3.45	N/A
Praxis Precision Medicines	$8.55M	1,025.72	-$303.27M	-$13.37	N/A

Summary

Praxis Precision Medicines beats Nurix Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Nurix Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Nurix Therapeutics (NASDAQ:NRIX) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, valuation, analyst recommendations, profitability, media sentiment and risk.

In the previous week, Nurix Therapeutics had 12 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 22 mentions for Nurix Therapeutics and 10 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.67 beat Nurix Therapeutics' score of 0.30 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Nurix Therapeutics	3 Very Positive mention(s)	6 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Protagonist Therapeutics has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

Protagonist Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	181.51	-$130.15M	-$1.81	N/A
Nurix Therapeutics	$83.98M	28.06	-$264.46M	-$3.45	N/A

Protagonist Therapeutics presently has a consensus target price of $116.93, indicating a potential downside of 9.98%. Nurix Therapeutics has a consensus target price of $34.08, indicating a potential upside of 50.05%. Given Nurix Therapeutics' higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.94
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79

Protagonist Therapeutics has a net margin of -154.88% compared to Nurix Therapeutics' net margin of -928.44%. Protagonist Therapeutics' return on equity of -17.76% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Protagonist Therapeutics beats Nurix Therapeutics on 11 of the 17 factors compared between the two stocks.

Get Nurix Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRIX vs. The Competition

Export

Metric	Nurix Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.39B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-6.58	20.85	27.11	24.26
Price / Sales	28.06	314.01	587.92	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	4.29	8.49	10.75	6.29
Net Income	-$264.46M	$23.83M	$3.58B	$330.66M
7 Day Performance	-6.93%	-3.56%	-2.06%	-1.32%
1 Month Performance	33.98%	6.31%	3.32%	-0.64%
1 Year Performance	78.96%	48.30%	26.35%	19.08%

Nurix Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRIX Nurix Therapeutics	3.5387 of 5 stars	$22.71 -1.5%	$34.08 +50.1%	+82.6%	$2.39B	$83.98M	N/A	300	Earnings Report Analyst Forecast Gap Down
IBRX ImmunityBio	2.9886 of 5 stars	$8.91 -5.6%	$14.20 +59.4%	+177.2%	$9.89B	$113.29M	N/A	590	Gap Down
NUVL Nuvalent	2.2746 of 5 stars	$123.72 0.0%	$127.73 +3.2%	+53.1%	$9.77B	N/A	N/A	40
KYMR Kymera Therapeutics	1.8857 of 5 stars	$114.76 +1.1%	$121.41 +5.8%	+148.2%	$9.34B	$39.21M	N/A	170	Analyst Downgrade Gap Down
PRAX Praxis Precision Medicines	3.0629 of 5 stars	$313.50 -1.6%	$569.63 +81.7%	+522.4%	$8.88B	$8.55M	N/A	110	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRIX) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nurix Therapeutics (NRIX) Competitors

NRIX vs. IBRX, NUVL, KYMR, PRAX, and PTGX

How does Nurix Therapeutics compare to ImmunityBio?

Summary

How does Nurix Therapeutics compare to Nuvalent?

Summary

How does Nurix Therapeutics compare to Kymera Therapeutics?

Summary

How does Nurix Therapeutics compare to Praxis Precision Medicines?

Summary

How does Nurix Therapeutics compare to Protagonist Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX vs. The Competition

Nurix Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nurix Therapeutics (NRIX) Competitors

NRIX vs. IBRX, NUVL, KYMR, PRAX, and PTGX

How does Nurix Therapeutics compare to ImmunityBio?

Which has preferable earnings & valuation, IBRX or NRIX?

Do analysts rate IBRX or NRIX?

Is IBRX or NRIX more profitable?

Does the media favor IBRX or NRIX?

Which has more volatility & risk, IBRX or NRIX?

Do insiders and institutionals believe in IBRX or NRIX?

Summary

How does Nurix Therapeutics compare to Nuvalent?

Do insiders and institutionals believe in NUVL or NRIX?

Do analysts rate NUVL or NRIX?

Which has more volatility & risk, NUVL or NRIX?

Which has better earnings & valuation, NUVL or NRIX?

Does the media prefer NUVL or NRIX?

Is NUVL or NRIX more profitable?

Summary

How does Nurix Therapeutics compare to Kymera Therapeutics?

Is KYMR or NRIX more profitable?

Which has more volatility and risk, KYMR or NRIX?

Do analysts rate KYMR or NRIX?

Which has stronger earnings and valuation, KYMR or NRIX?

Does the media refer more to KYMR or NRIX?

Summary

How does Nurix Therapeutics compare to Praxis Precision Medicines?

Do analysts rate NRIX or PRAX?

Does the media favor NRIX or PRAX?

Do institutionals & insiders believe in NRIX or PRAX?

Which has more risk and volatility, NRIX or PRAX?

Is NRIX or PRAX more profitable?

Which has better valuation and earnings, NRIX or PRAX?

Summary

How does Nurix Therapeutics compare to Protagonist Therapeutics?

Does the media refer more to PTGX or NRIX?

Which has more volatility and risk, PTGX or NRIX?

Which has stronger earnings and valuation, PTGX or NRIX?

Do analysts recommend PTGX or NRIX?

Is PTGX or NRIX more profitable?

Do insiders & institutionals have more ownership in PTGX or NRIX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRIX vs. The Competition

Nurix Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools